SCHEMBL2762045

SCHEMBL2762045

Cc1ccc(COc2cccc3c2C(=O)OC(C)(C)O3)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.41
KMT2A Q03164 3/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.40
MAOA P21397 2/20 0.40
HPD P32754 2/20 0.40
PRKCA P17252 1/20 0.40
NPC1 O15118 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
RAB9A P51151 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAPK1 P28482 1/20 0.39
HTR1A P08908 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2761788 0.90 MAOB (0.43) MAOBKMT2AMAPTMEN1MAOA
SCHEMBL31091551 0.89 PRKCA (0.49) MAOBMAPTMAOAPRKCATDP1
SCHEMBL2762001 0.89 PRKCA (0.49) MAOBMAPTMAOAPRKCATDP1
SCHEMBL1949049 0.88 NPC1 (0.43) MAOBKMT2AMAPTMEN1MAOA
SCHEMBL15356467 0.78 CETP (0.41) MAOBMAPTPRKCATDP1L3MBTL1
SCHEMBL15349916 0.78 ALDH1A1 (0.39) KMT2APRKCATDP1L3MBTL1MAPK1
SCHEMBL21012608 0.77 ALDH1A1 (0.38) KMT2APRKCATDP1L3MBTL1MAPK1
SCHEMBL15349588 0.77 ALDH1A1 (0.38) KMT2APRKCANPC1TDP1L3MBTL1
SCHEMBL13517102 0.76 MAOB (0.38) MAOBMAPTMAOAPRKCATDP1
SCHEMBL23655043 0.75 ALDH1A1 (0.48) KMT2AMAPTMEN1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324405-B2 Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors FIBROGEN, INC. (US) 2012-12-04 US disclosed
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. 2010-12-30 US disclosed
WO-2009100250-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS FIBROGEN, INC. (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331400-A1 CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS HIF1AN, HIF1A, EGLN2 MAOB 424/4885KMT2A 832/4885MAPT 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.